Literature DB >> 8616093

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.

J Amiral1, M Wolf, A Fischer, C Boyer-Neumann, A Vissac, D Meyer.   

Abstract

Antibodies to heparin-PF4 (H-PF4) complexes have been tested and isotyped in 38 patients who developed severe heparin-induced thrombocytopenia (type II HIT). All patients had a platelet count <120x10(9)/1 or a reduction of > 30% of the initial value, occurring at least 5d after the onset of heparin. Thrombocytopenia, which rapidly reversed following the withdrawal of heparin, was associated with thrombosis in nine patients. Although IgG isotypes were found in most cases (n=26), the presence of only IgM and/or IgA was observed in 12 patients, including three cases showing a thrombotic complication. Our results indicate that type II HIT may be induced by IgA and /or IgM anti-H-PF4 antibodies even in the absence of IgG isotypes. This finding demonstrates that platelet Fc receptors (FcgammaRII) are not necessarily involved in the pathogenicity of heparin-dependent antibodies and emphasizes the major role of platelet PF4 receptors. The increased expression of the latter following a slight activation by thrombin, and the subsequent binding of IgM and IgA antibodies to H-PF4 on the platelet surface, may directly trigger platelet activation aggregation and thrombosis. Alternatively, thrombocytopenia could be indirectly induced through the mediation of neutrophils, monocytes and lymphocytes which expose receptors for IgA (FcalphaR) or IgM FcmuR). IgM-platelet complexes may also bind and activate complement, leading to platelet activation or destruction. Moreover, the reactivity of the antibodies with glycosaminoglycans-PF4 complexes present on the endothelial surface could also induce endothelial lesions and promote procoagulant activity and predisposition to thrombosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616093     DOI: 10.1046/j.1365-2141.1996.407945.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Authors:  Albrecht Leo; Susanne Winteroll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 3.  New data on the pharmacology of heparin and low molecular weight heparins.

Authors:  M M Samama; L Bara; I Gouin-Thibault
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 5.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

6.  Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Gonzalo Díaz; Patricia Hidalgo; Isabel Pizarro; Eric Jara; Patricio Rojas; Guillermo Quiroga; Rodrigo Moore-Carrasco
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 7.  Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge.

Authors:  Volker Assfalg; Norbert Hüser
Journal:  World J Transplant       Date:  2016-03-24

Review 8.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 9.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

10.  Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature.

Authors:  Indraneel Datta; Chad G Ball; Lucas Rudmik; S Morad Hameed; John B Kortbeek
Journal:  J Trauma Manag Outcomes       Date:  2010-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.